Breaking Down Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.

Comparing Revenue Trends of Taro and Xencor Over a Decade

__timestamp	Taro Pharmaceutical Industries Ltd.	Xencor, Inc.
Wednesday, January 1, 2014	759285000	9520000
Thursday, January 1, 2015	862944000	27762000
Friday, January 1, 2016	950751000	87520000
Sunday, January 1, 2017	879387000	35711000
Monday, January 1, 2018	661913000	40603000
Tuesday, January 1, 2019	669893000	156700000
Wednesday, January 1, 2020	644769000	122694000
Friday, January 1, 2021	548970000	275111000
Saturday, January 1, 2022	561347000	164579000
Sunday, January 1, 2023	572952000	168338000
Monday, January 1, 2024	629182000

Data in motion

Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.

In the ever-evolving pharmaceutical landscape, understanding revenue trends is crucial for investors and industry analysts. Taro Pharmaceutical Industries Ltd. and Xencor, Inc. offer a fascinating case study. From 2014 to 2023, Taro's revenue peaked in 2016, reaching approximately 950 million, before experiencing a gradual decline, ending at around 630 million in 2023. This represents a 34% decrease from its peak. In contrast, Xencor, Inc. started with modest revenues, but by 2021, it had achieved a remarkable growth, peaking at nearly 275 million, a staggering 2800% increase from 2014. However, 2024 data for Xencor is missing, leaving room for speculation about its future trajectory. These trends highlight the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can significantly impact financial outcomes.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025